Table 1. Patient demographics.
| Parameter | Result |
| Number of Patients | 85 |
| Age in years, mean ± SD | 63.1 ± 8.6 |
| Male, n (mean ± SD %) | 57 (70.0 ± 47.3 %) |
| Medical history, n (%) | |
| Active cardiopulmonary disease† | 9 (10.6%) |
| Hemodialysis | 10 (11.8%) |
| Stroke | 7 (8.2%) |
| Recent non-HCC malignancy within 5 years | 9 (10.6%) |
| Diabetes | 27 (31.8%) |
| Lymphoma | 1 (1.2%) |
| Co-existent liver disease(s), n (%) | |
| Non-alcoholic fatty liver disease (NAFLD) | 1 (1.2%) |
| Hepatitis B | 3 (3.9%) |
| Autoimmune hepatitis | 1 (1.2%) |
| Hepatocellular carcinoma | 40 (47.1%) |
| Mean time from LT to Treatment Initiation in months (±SD) | 68.3 (±70.6) |
| Received more than one LT | 3 (3.5%) |
| Treatment-naïve, n (%) | 46 (54.1%) |
| Treatment-experienced, n (%) | 39 (45.9%) |
| Treatment prior to LT | 18 (46.2%) |
| Interferon/ribavirin | 15 (83.3%) |
| Sofosbuvir/ribavirin | 1 (5.6%) |
| Sofosbuvir/simeprevir | 2 (11.1%) |
| Treatment post-LT | 21 (53.8%) |
| Interferon/ribavirin | 10 (47.6%) |
| Sofosbuvir/interferon/ribavirin | 2 (9.5%) |
| Sofosbuvir/ribavirin | 4 (19.0%) |
| Sofosbuvir/simeprevir ± ribavirin | 4 (19.0%) |
| Ribavirin monotherapy | 1 (4.8%) |
| Stage of fibrosis at start of treatment, n (%) | |
| 0–1 | 33 (38.8%) |
| 2–3 | 18 (21.2%) |
| 4 | 34 (40%) |
| Presence of fibrosing cholestatic hepatitis | 1 (1.2%) |
| Immunosuppression therapy, n (%) | |
| Tacrolimus only | 30 (35.3%) |
| Tacrolimus + mycophenolate ± prednisone | 39 (45.9%) |
| Tacrolimus + sirolimus ± prednisone | 6 (7.1%) |
| Cyclosporine only | 3 (3.5%) |
| Cyclosporine + mycophenolate | 4 (4.7%) |
| Sirolimus + mycophenolate | 2 (2.4%) |
| Sirolimus + prednisone | 1 (1.2%) |
| Treatment regimen, n (%) | |
| Sofosbuvir/ledipasvir for 12 weeks | 18 (21.2%) |
| Sofosbuvir/ledipasvir + ribavirin for 12 weeks | 33 (38.8%) |
| Sofosbuvir/ledipasvir for 24 weeks | 29 (34.1%) |
| Sofosbuvir/ledipasvir + ribavirin for 24 weeks | 5 (5.9%) |
Abbreviations: COPD, chronic obstructive pulmonary disease; HCC, hepatocellular carcinoma; NAFLD, nonalcoholic fatty liver disease; SD, standard deviation; LT, liver transplantation.
†
Examples of active cardiopulmonary diseases include coronary artery disease, heart failure, chronic obstructive pulmonary disease, and idiopathic pulmonary fibrosis.